[1] |
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Impurities in New Drug Substances Q3A(R2)[R], 2006. https://database.ich.org/sites/default/files/Q3A_R2__Guideline.pdf
|
[2] |
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Impurities in New Drug Products Q3B(R2)[R], 2006. https://database.ich.org/sites/default/files/Q3B_R2__Guideline.pdf
|
[3] |
PRAMANIK B, LEE M S, CHEN G D. Characterization of impurities and degradants using mass spectrometry[M]. Hoboken: Wiley, 2011.
|
[4] |
WANG J, XU Y, WEN C M, et al. Application of a trap-free two-dimensional liquid chromatography combined with ion trap/time-of-flight mass spectrometry for separation and characterization of impurities and isomers in cefpiramide[J]. Anal Chim Acta, 2019, 992: 42-54.
|
[5] |
GILLESPIE T A, WINGER B E. Mass spectrometry for small molecule pharmaceutical product development: A review[J]. Mass Spectrom Rev, 2011, 30(3): 479-490.
doi: 10.1002/mas.20289
pmid: 21500245
|
[6] |
LIU Y Z, NOMIJN E P, VERNIEST G, et al. Mass spectrometry-based structure elucidation of small molecule impurities and degradation products in pharmaceutical development[J]. Trends Analyt Chem, 2019, 121: 115670.
|
[7] |
QIU F H, NORWOOD D L. Identification of pharmaceutical impurities[J]. J Liq Chromatogr R T, 2007, 30(5-7): 877-935.
|
[8] |
CORCORAN O, SPRAUL M. LC-NMR-MS in drug discovery[J]. Drug Discov Today, 2003, 8(14): 624-631.
pmid: 12867148
|
[9] |
SHARMAN G J, JONES I C. Critical investigation of coupled liquid chromatography-NMR spectroscopy in pharmaceutical impurity identification[J]. Magn Reson Chem, 2003, 41: 448-454.
|
[10] |
EXARCHOU V, GODEJOHANN M, BEEK T A, et al. LC-UV-Solid-Phase Extraction-NMR-MS combined with a cryogenic flow probe and its application to the identification of com-pounds present in greek oregano[J]. Anal Chem, 2003, 75(22): 6288-6294.
|
[11] |
CLARKSON C, HANSEN S H, JAROSZEWSKI J W. Hyphenation of solid-phase extraction with liquid chro-matography and nuclear magnetic resonance: Application of HPLC-DAD-SPE-NMR to identification of constituents of Kanahia laniflora[J]. Anal Chem, 2005, 77(11): 3547-3553.
|
[12] |
LIU H B, ZHENG A M, YU H Y, et al. Identification of three novel polyphenolic compounds, origanine A-C, with unique skeleton from Origanum vulgare L. using the hyphenated LC-DAD-SPE-NMR/MS methods[J]. J Agric Food Chem, 2012, 60: 129-135.
|
[13] |
SANDVOSS M, BARDSLEY B, BECK T L, et al. HPLC-SPE-NMR in pharmaceutical development: capabilities and applications[J]. Magn Reson Chem, 2005, 43(9): 762-770.
|
[14] |
JAROSZEWSKI J W. Hyphenated NMR methods in natural products research, part 2: HPLC-SPE-NMR and other new trends in NMR hyphenation[J]. Planta Med, 2005, 71(9): 795-802.
pmid: 16206031
|
[15] |
WANG Y L, TANG H R, XIAO C N. Important roles of the hyphenated HPLC-DAD-MS-SPE-NMR technique in metabonomics[J]. Magn Reson Chem, 2009, 47(S1): 157-162.
|
[16] |
SEGER C, GODEJOHANN M, TSENG LH, et al. LC-DAD-MS/SPE-NMR hyphenation. A tool for the analysis of pharmaceutically used plant extracts: Identification of iso-baric iridoid glycoside regioisomers from Harpagophytum procumbens[J] Anal Chem, 2005, 77(3): 878-885.
|
[17] |
LIU F, WANG Y N, LI Y, et al. Minor nortriterpenoids from the twigs and leaves of Rhododendron latoucheae[J]. J Nat Prod, 2018, 81(8): 1721-1733.
|
[18] |
PAN C K, LIU F, JI Q, et al. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development[J]. J Pharm Biomed Anal, 2006, 40(3): 581-590.
pmid: 16242883
|
[19] |
RINALDI F, FAN J Y, PATHIRANA C, et al. Semi-preparative LC-SPE-cryoflow NMR for impurity identifications: use of mother liquor as a better source of impurities[J]. Magn Reson Chem, 2013, 51(9): 517-522.
|
[20] |
HARČA M, HABINOVEC I, MESTROVIC E, et al. Rapid identification of unknown impurities in 3-Bromo-5-(trifluoromethyl) aniline by LC-SPE/NMR[J]. Croat Chem Acta, 2016, 89(4): 543-547.
|
[21] |
PALLER C J, ANTONARAKIS E S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer[J]. Drug Des Dev Ther, 2011, 5: 117-124.
doi: 10.2147/DDDT.S13029
pmid: 21448449
|
[22] |
WANG Y Y, FENG F, CHEN L, et al. Isolation, identification and characterization of potential impurities in cabazitaxel and their formation[J]. Magn Reson Chem, 2014, 52(12): 783-788.
|
[23] |
LI C Y, LAN G J, JIANG J Y, et al. Development and validation of a stability-indicating HPLC Method for the determination of the impurities in cabazitaxel[J]. J Chromatographia, 2015, 78(11-12): 825-831.
|
[24] |
RAJAN N, BASHA K A. A validated stability indicating UPLC method for simultaneous determination of related substances, and degradation products of cabazitaxel drug substance and its pharmaceutical injection forms[J]. J Pharm Sci Res, 2014, 6(12): 411-419.
|
[25] |
FUJI K, TANAK K, Li B, et al. Taxchinin a: A diterpenoid from Taxus chinensis[J]. Tetra Lett, 1992, 33(51): 7915-7916.
|
[26] |
CHATTOPADHYAY SK, SAHA G C, SHARMA R P, et al. A rearranged taxane from the himalayan yew Taxus wallichiana[J]. Phytochemistry, 1996, 42(3): 787-788.
|
[27] |
SHEN Y C, CHEN Y J, CHEN C Y. Taxane diterpenoids from the seeds of Chinese yew Taxus chinensis[J]. Phytochemistry, 1999, 52(8): 1565-1569.
|
[28] |
DAS B, SRINIVAS K V N S, RAVINDRANATH N, et al. Acid catalyzed conversions of toxoids[J]. J Ind Chem Soc, 2001, 78: 667-670.
|
[29] |
YU D H, KANG W, HAO F, et al. Spectroscopic studies and structural elucidation of cabazitaxel[J]. Chinese J Magn Reson, 2017, 34(2): 191-199.
|
|
余大海, 康旺, 郝福, 等. 卡巴他赛结构确证的波谱学研究[J]. 波谱学杂志, 2017, 34(2): 191-199.
doi: 10.11938/cjmr20170208
|